Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, ...
Editas’ study is being conducted to confirm safety and escalate dosing to where the editing may begin to show a strong effect in reversing the condition. (Getty Images) Editas Medicine may have been ...
Genome editing lets scientists rewrite DNA, the instruction manual inside every living cell, with a precision that was unthinkable a generation ago. Technologies such as CRISPR have made this almost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results